Immunohistochemical profiling of the tumour microenvironment in borderline and malignant ovarian tumours in young women

O'Νeill,Danielle; Rice,Kirstie; Bhatnagar,Anjali; Kearns,Daniel; Berditchevski,Fedor; El-Ghobashy,Alaa; Shaaban,Abeer M.

doi:10.3892/ol.2023.13763

Immunohistochemical profiling of the tumour microenvironment in borderline and malignant ovarian tumours in young women

Authors:
- Danielle O'Νeill
- Kirstie Rice
- Anjali Bhatnagar
- Daniel Kearns
- Fedor Berditchevski
- Alaa El-Ghobashy
- Abeer M. Shaaban
View Affiliations

Affiliations: Department of Gynaecological Oncology, The Royal Wolverhampton NHS Trust, New Cross Hospital, Wolverhampton, West Midlands WV10 0QP, UK, Department of Cellular Pathology, The Royal Wolverhampton NHS Trust, New Cross Hospital, Wolverhampton, West Midlands WV10 0QP, UK, Department of Cellular Pathology, The Royal Wolverhampton NHS Trust, New Cross Hospital, Wolverhampton, West Midlands WV10 0QP, UK, Department of Cellular Pathology, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, Edgbaston, Birmingham B15 2GW, UK, Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK, Department of Gynaecological Oncology, The Royal Wolverhampton NHS Trust, New Cross Hospital, Wolverhampton, West Midlands WV10 0QP, UK
Published online on: March 15, 2023 https://doi.org/10.3892/ol.2023.13763
Article Number: 177
Copyright : © O'Νeill et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer is a major cause of cancer‑related deaths in women. Our previous study highlighted the interaction between cancer cells and the host immune response in solid cancers. The present study aimed to analyse the proportion, density and distribution of T and B lymphocytes within the tumour and surrounding stroma, and their prognostic significance in young women with borderline and malignant ovarian surface epithelial tumours. Full clinicopathological and outcome data were collected for 57 women aged <50 years diagnosed between January 2010 and December 2015. Representative tumour sections were stained for CD3 (T cells) and CD20 (B cells) and tumour‑infiltrating lymphocytes (TILs) were scored following the TILs Working Group Recommendations and described as stromal, intra‑tumoural, lymphoid aggregates and touching lymphocytes. Data were statistically analysed and the association with clinicopathological variables was assessed. The median age was 41 years and the most common histological type was serous carcinoma (n=21). The risk of malignancy index was a significant predictor of ovarian cancer diagnosis (P<0.05). A total of 15 out of 34 patients with cancer died. There was significantly greater stromal infiltration of CD3 and CD20 TILs (P=0.01 and P=0.03, respectively) and higher intratumoral CD20 expression in ovarian epithelial cancers compared with borderline tumours. The highest CD3 stroma count and density were observed in serous carcinoma, which also exhibited the highest numbers of CD3 and CD20 aggregates. There was no statistically significant difference between touching lymphocytes and tumour histological subtype. There was no significant association between TIL expression and patient survival. The count, distribution and density of T and B lymphocytes in ovarian tumours varied depending on tumour type and invasiveness. Their topographic distribution within the tumour and surrounding stroma did not impact prognosis in young women with ovarian cancer. TIL analysis in an older age group of women with ovarian tumours is ongoing to determine its potential prognostic significance.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Cancer Research UK, . Available from. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/vulval-cancer#heading-ZeroSeptember 14–2018
3	Lengyel E: Ovarian cancer development and metastasis. Am J Pathol. 177:1053–1064. 2010. View Article : Google Scholar : PubMed/NCBI
4	Giornelli GH: Management of relapsed ovarian cancer: A review. Springerplus. 5:11972016. View Article : Google Scholar : PubMed/NCBI
5	Ahmed N and Stenvers KL: Getting to know ovarian cancer ascites: Opportunities for targeted therapy-based translational research. Front Oncol. 3:2562013. View Article : Google Scholar : PubMed/NCBI
6	Kipps E, Tan DSP and Kaye SB: Meeting the challenge of ascites in ovarian cancer: New avenues for therapy and research. Nat Rev Cancer. 13:273–282. 2013. View Article : Google Scholar : PubMed/NCBI
7	Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, et al: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 348:203–213. 2003. View Article : Google Scholar : PubMed/NCBI
8	Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, et al: Assessing tumor-infiltrating lymphocytes in solid tumors: A practical review for pathologists and proposal for a standardized method from the international immunooncology biomarkers working group: Part 1: Assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further research. Adv Anat Pathol. 24:235–251. 2017. View Article : Google Scholar : PubMed/NCBI
9	Garnelo M, Tan A, Her Z, Yeong J, Lim CJ, Chen J, Lim KH, Weber A, Chow P, Chung A, et al: Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. Gut. 66:342–351. 2017. View Article : Google Scholar : PubMed/NCBI
10	Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, et al: Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA. 102:18538–18543. 2005. View Article : Google Scholar : PubMed/NCBI
11	Toss MS, Miligy I, Al-Kawaz A, Alsleem M, Khout H, Rida PC, Aneja R, Green AR, Ellis IO and Rakha EA: Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast. Mod Pathol. 31:1226–1236. 2018. View Article : Google Scholar : PubMed/NCBI
12	Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JPA, Hitre E, et al: Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02–98. J Clin Oncol. 31:860–867. 2013. View Article : Google Scholar : PubMed/NCBI
13	Hwang WT, Adams SF, Tahirovic E, Hagemann IS and Coukos G: Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis. Gynecol Oncol. 124:192–198. 2012. View Article : Google Scholar : PubMed/NCBI
14	Burstein HJ, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P, Colleoni M, Denkert C, Piccart-Gebhart M, Regan M, et al: Estimating the benefits of therapy for early stage breast cancer. The St gallen international consensus guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 30:1541–1557. 2019. View Article : Google Scholar : PubMed/NCBI
15	Kos Z, Roblin E, Kim RS, Michiels S, Gallas BD, Chen W, van de Vijver KK, Goel S, Adams S, Demaria S, et al: Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. NPJ Breast Cancer. 6:172020. View Article : Google Scholar : PubMed/NCBI
16	de Lima CA, Jammal MP, Etchebehere RM, Murta EFC and Nomelini RS: Lymphocytes in peritumoral stroma: Evaluation in epithelial ovarian neoplasms. Immunol Invest. 49:397–405. 2020. View Article : Google Scholar : PubMed/NCBI
17	Hao J, Yu H, Zhang T, An R and Xue Y: Prognostic impact of tumor-infiltrating lymphocytes in high grade serous ovarian cancer: A systematic review and meta-analysis. Ther Adv Med Oncol. 31:17588359209672412020.PubMed/NCBI
18	Darb-Esfahani S, Kolaschinski I, Trillsch F, Mahner S, Concin N, Vergote I, Nieuwenhuysen EL, Achimas-Cadariu P, Glajzer J, Woopen H, et al: Morphology and tumour-infiltrating lymphocytes in high-stage, high-grade serous ovarian carcinoma correlated with long-term survival. Histopathology. 73:1002–1012. 2018. View Article : Google Scholar : PubMed/NCBI
19	Nielsen JS, Sahota RA, Milne K, Kost SE, Nesslinger NJ, Watson PH and Nelson BH: CD20+ tumor-infiltrating lymphocytes have an atypical CD27-memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res. 18:3281–3292. 2012. View Article : Google Scholar : PubMed/NCBI
20	Truxova I, Kasikova L, Hensler M, Skapa P, Laco J, Pecen L, Belicova L, Praznovec I, Halaska MJ, Brtnicky T, et al: Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients. J Immunother Cancer. 4:1392018. View Article : Google Scholar : PubMed/NCBI
21	Lo CS, Sanii S, Kroeger DR, Milne K, Talhouk A, Chiu DS, Rahimi K, Shaw PA, Clarke BA and Nelson BH: Neoadjuvant chemotherapy of ovarian cancer results in three patterns of tumor-infiltrating lymphocyte response with distinct implications for immunotherapy. Clin Cancer Res. 23:925–934. 2017. View Article : Google Scholar : PubMed/NCBI
22	Germain C, Gnjatic S, Tamzalit F, Knockaert S, Remark R, Goc J, Lepelley A, Becht E, Katsahian S, Bizouard G, et al: Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am J Respir Crit Care Med. 189:832–844. 2014. View Article : Google Scholar : PubMed/NCBI
23	Ladányi A, Kiss J, Mohos A, Somlai B, Liszkay G, Gilde K, Fejös Z, Gaudi I, Dobos J and Tímár J: Prognostic impact of B-cell density in cutaneous melanoma. Cancer Immunol Immunother. 60:1729–1738. 2011. View Article : Google Scholar : PubMed/NCBI
24	Iglesia MD, Vincent BG, Parker JS, Hoadley KA, Carey LA, Perou CM and Serody JS: Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. Clin Cancer Res. 20:3818–3829. 2014. View Article : Google Scholar : PubMed/NCBI
25	Nedergaard BS, Ladekarl M, Nyengaard JR and Nielsen K: A comparative study of the cellular immune response in patients with stage IB cervical squamous cell carcinoma. Low numbers of several immune cell subtypes are strongly associated with relapse of disease within 5 years. Gynecol Oncol. 108:106–111. 2008. View Article : Google Scholar : PubMed/NCBI
26	Arias-Pulido H, Cimino-Mathews A, Chaher N, Qualls C, Joste N, Colpaert C, Marotti JD, Foisey M, Prossnitz ER, Emens LA and Fiering S: The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome. Breast Cancer Res Treat. 171:273–282. 2018. View Article : Google Scholar : PubMed/NCBI
27	Milne K, Köbel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, Watson PH and Nelson BH: Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One. 4:e64122009. View Article : Google Scholar : PubMed/NCBI
28	Montfort A, Pearce O, Maniati E, Vincent BG, Bixby L, Böhm S, Dowe T, Wilkes EH, Chakravarty P, Thompson R, et al: A strong B-cell response is part of the immune landscape in human high-grade serous ovarian metastases. Clin Cancer Res. 23:250–262. 2017. View Article : Google Scholar : PubMed/NCBI
29	Maley CC, Aktipis A, Graham TA, Sottoriva A, Boddy AM, Janiszewska M, Silva AS, Gerlinger M, Yuan Y, Pienta KJ, et al: Classifying the evolutionary and ecological features of neoplasms. Nat Rev Cancer. 17:605–619. 2017. View Article : Google Scholar : PubMed/NCBI
30	Valastyan S and Weinberg RA: Tumor metastasis: Molecular insights and evolving paradigms. Cell. 147:275–292. 2011. View Article : Google Scholar : PubMed/NCBI
31	Hensler M, Kasikova L, Fiser K, Rakova J, Skapa P, Laco J, Lanickova T, Pecen L, Truxova I, Vosahlikova S, et al: M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer. J Immunother Cancer. 8:e0009792020. View Article : Google Scholar : PubMed/NCBI
32	Dai D, Liu L, Huang H, Chen S, Chen B, Cao J, Luo X, Wang F, Luo R and Liu J: Nomograms to predict the density of tumor-infiltrating lymphocytes in patients with high-grade serous ovarian cancer. Front Oncol. 25:5904142021. View Article : Google Scholar : PubMed/NCBI
33	James FR, Jiminez-Linan M, Alsop J, Mack M, Song H, Brenton JD, Pharoah PDP and Ali HR: Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer. BMC Cancer. 20:6572017. View Article : Google Scholar : PubMed/NCBI
34	Geomini P, Kruitwagen R, Bremer GL, Cnossen J and Mol BWJ: The accuracy of risk scores in predicting ovarian malignancy: A systematic review. Obstet Gynecol. 113((2 Pt 1)): 384–394. 2009. View Article : Google Scholar : PubMed/NCBI
35	Zhang S, Yu S, Hou W, Li X, Ning C, Wu Y, Zhang F, Jiao YF, Lee LTO and Sun L: Diagnostic extended usefulness of RMI: Comparison of four risk of malignancy index in preoperative differentiation of borderline ovarian tumors and benign ovarian tumors. J Ovarian Res. 12:872019. View Article : Google Scholar : PubMed/NCBI
36	Robinson-Smith TM, Isaacsohn I, Mercer CA, Zhou M, Van Rooijen N, Husseinzadeh N, McFarland-Mancini MM and Drew AF: Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Cancer Res. 67:5708–5716. 2007. View Article : Google Scholar : PubMed/NCBI